TAK

시장 영업 전: 15.23 0.30 +2.01%

다케다약품공업 ADR (TAK)

개요 뉴스 가격 이력 옵션 체인 토론 예측 배당 이력

Relative Volume:

다케다약품공업 ADR Stock (TAK) Company Profile

Takeda Pharmaceutical Co Adr

Healthcare (1155)

@takedapharma

최신 SEC 제출 서류

TAK's Discussions on Twitter

TAK을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TAK Takeda Pharmaceutical Co Adr	14.93	45.01B	30.25B	1.37B	5.08B	0.4257
ZTS Zoetis Inc	146.85	67.28B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.19	45.61B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	13.31	15.25B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	284.25	12.77B	2.76B	1.11B	898.10M	22.77

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-04-02	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2023-03-16	업그레이드	BofA Securities	Neutral → Buy
2022-07-19	업그레이드	Cowen	Market Perform → Outperform
2021-10-07	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-04-19	다운그레이드	JP Morgan	Overweight → Neutral
2019-11-01	개시	Cowen	Market Perform
2019-08-15	다운그레이드	Daiwa Securities	Outperform → Neutral

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

다케다약품공업 ADR (TAK) 재무 분석

다케다약품공업 ADR (TAK)

다케다약품공업 ADR Stock (TAK) Company Profile

TAK을(를) 다른 주식과 비교

다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades

다케다약품공업 ADR 주식(TAK)의 최신 뉴스

TAK vs. DSNKY: Which Stock Is the Better Value Option? - Yahoo Finance

Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline - GlobeNewswire Inc.

Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading - MSN

Asian ADRs Take A Hit As S&P Asia 50 Dips - Finimize

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? - Yahoo

PD Stock on the Rise: A Promising Investment - The InvestChronicle

TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance

Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle

China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets

Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Charles Schwab Trying To Close In On Key Technical Measure - Inkl

Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle

Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Investor's Business Daily

XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN

Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN

Vyvanse Leaks: Beyond The Headlines - truthorfiction.com

IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR

IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR

Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News

Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News

Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily

Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily

GFL Shares Experience Surge in Value - Knox Daily

UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily

Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News

Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater

Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily

Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily

Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN

다케다약품공업 ADR (TAK) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TAK과 유사한 종목